Tag: DRUG ELUTING STENTS
SWEDEPAD unplanned interim analysis shows no difference in all-cause mortality for...
An unplanned interim analysis of the registry-based SWEDEPAD clinical trial, in which patients with peripheral arterial disease received treatment with paclitaxel-coated (drug-coated balloons or...
MHRA issues medical device alert for paclitaxel use in the UK
Do not use paclitaxel drug-coated balloons (DCBs) or drug-eluting stents (DESs) in the routine treatment of patients with intermittent claudication until further notice, a...
Without additional long-term and patient-level data, Katsanos et al’s conclusion is...
By Thomas Zeller
The Katsanos et al meta-analysis reports an increased risk of mortality beyond one year across randomised studies of paclitaxel-coated balloons (DCB) and...
Stem cell therapy is the future of critical limb ischaemia management
Addressing the audience at the 33rd annual meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE; 22–25 September, Lisbon, Portugal), Sanjiv Sharma...
